Table E-3. Quality and applicability table for KQ 3 studies—postdischarge treatment for UA/NSTEMI

| **Study** | **Intervention/Comparator** | **Study Quality** | **Limitations to Applicability** |
| --- | --- | --- | --- |
| Alexander, 2008108CRUSADE | * Clopidogrel
* No clopidogrel
 | Fair | * None
 |
| Aronow, 2008109BRAVO | * ASA <162mg/day, maintenance dose: 100 mg
* ASA >162 mg/day, maintenance dose: 325 mg
 | Good | * Study's cointerventions did not adequately reflect routine clinical practice (e.g., use of medical therapy for secondary prevention – antiplatelet agents, HTN/DM/lipid control)
 |
| Banerjee, 2011110 | * No PPI
* PPI
 | Good | * None
 |
| Barada, 2008111 | * PPI
* Placebo
 | Poor | * Study eligibility criteria were poorly described or not appropriate
* Study exclusion criteria were poorly described or not appropriate
* Study conducted solely outside the US
* Study was conducted only at a single site
 |
| Bernardi, 2007112RACS | * Dual therapy: clopidogrel 30 day + ASA
* Dual therapy: clopidogrel 180 day + ASA
 | Fair | * Study conducted solely outside the US
 |
| Bhatt, 2010113COGENT | * Omeprazole 20 mg
* Placebo
 | Good | * None
 |
| Bhurke, 2012114 | * Clopidogrel + PPI
* Clopidogrel
 | Fair | * Study eligibility criteria were poorly described or not appropriate
* Study exclusion criteria were poorly described or not appropriate
 |
| Bonde, 2010115 | * Placebo
* Clopidogrel
 | Fair | * Study conducted solely outside the US
 |
| Buresly, 2005116 | * ASA
* Warfarin
 | Good | * Study conducted solely outside the US
 |
| Butler, 2009117 | * DES with clopidogrel intended duration ≤3 mo
* DES with clopidogrel intended duration
* 6 mo
* BMS with clopidogrel intended duration ≤3 mo
* BMS with clopidogrel intended duration 6 mo
* DES with clopidogrel intended duration ≥12 mo
* BMS with clopidogrel intended duration ≥12 mo
 | Fair | * Study conducted solely outside the US
 |
| Charlot, 2010118 | * No PPI
* PPI
* Placebo
* Clopidogrel
 | Good | * None
 |
| Charlot, 2011119 | * PPI
* No PPI
 | Good | * None
 |
| Charlot, 2012120 | * Clopidogrel up to 90 days
* Clopidogrel >90 days
 | Fair | * Study did not report participants’ baseline characteristics
 |
| Cheng, 2010121T-ACCORD Registry | * ASA
* Clopidogrel
* Dual therapy (ASA + clopidogrel)
 | Good | * Study conducted solely outside the US
 |
| Chitose, 2011122KICS | * PPI
* No PPI
 | Good | * None
 |
| Evanchan, 2010123 | * PPI
* Placebo
 | Good | * Study exclusion criteria were poorly described or not appropriate
* Study was conducted only at a single site
 |
| Fosbol, 2012124 | * ASA
* Warfarin
* ASA + clopidogrel
* ASA + clopidogrel + warfarin
 | Fair | * None
 |
| Gao, 2009125 | * Omeprazole 40 mg loading, 20 mg maintenance
 | Poor | * Study did not report participants' baseline characteristics
* Study did not report participants' comorbid conditions.
* Study eligibility criteria were poorly described or not appropriate
* Study exclusion criteria were poorly described or not appropriate
* Study conducted solely outside the US
 |
| Gaspar, 2010126 | * PPI
* No PPI
 | Good | * None
 |
| Goodman, 2012127Mahaffey, 2011128Wallentin, 200982PLATO | * PPI
* Placebo
 | Good | * None
 |
| Gupta, 2010129 | * PPI
* Placebo
 | Fair | * Study eligibility criteria were poorly described or not appropriate
* Study exclusion criteria were poorly described or not appropriate
* Study was conducted only at a single site
 |
| Gwon, 2012130 | * ASA + clopidogrel 6 mo
* ASA + clopidogrel 12 mo
 | Good | * Study conducted solely outside the US
 |
| Harjai, 2009131 | * ASA 81–325 mg/day + clopidogrel >12 mo (whole cohort any stent), Maintenance dose: ASA 81–325 mg/day + clopidogrel 75 mg/day or ticlopidine (dose not specified).
* ASA 81–325 mg/day + clopidogrel ≤ 12 mo (whole cohort any stent), Maintenance dose: ASA 81–325 mg/day + clopidogrel 75 mg/day or ticlopidine (dose not specified).
 | Good | * None
 |
| Harjai, 2011132GHOST | * ASA, maintenance dose: 81 mg/day
* ASA, maintenance dose: 162-325 mg/day
 | Fair | * Study selectively recruited participants who demonstrated a history of favorable or unfavorable response to drug or other interventions for the condition.
 |
| Harjai, 2011133 | * PPI
* No PPI
 | Good | * None
 |
| Ho, 2007134 | * Continued clopidogrel
* Discontinued clopidogrel
 | Fair | * Population was almost entirely male.
 |
| Ho, 2009135 | * PPI
* Placebo
 | Good | * None
 |
| Hsiao, 2011136 | * PPI
* No PPI
 | Good | * None
 |
| Jang, 2011137 | * Warfarin
* Placebo
 | Poor | * Study eligibility criteria were poorly described or not appropriate
* Study exclusion criteria were poorly described or not appropriate
* Study conducted solely outside the US
 |
| Juurlink, 2009138 | * Clopidogrel + nonfatal MI in 90 days
* Clopidogrel
 | Good | * Study conducted solely outside the US
 |
| Karjalainen, 2007139 | * Warfarin
* Placebo
 | Good | * Study conducted solely outside the US
 |
| Konstantino, 2006140 | * ASA + ticlopidine/ clopidogrel
* ASA + ticlopidine/clopidogrel +warfarin
 | Fair | * Study eligibility criteria were poorly described or not appropriate
* Study exclusion criteria were poorly described or not appropriate
* Study conducted solely outside the US
 |
| Kreutz, 2010141 | * PPI
* Placebo
 | Good | * Study eligibility criteria were poorly described or not appropriate
* Study conducted solely outside the US
 |
| Lamberts, 2013142 | * Clopidogrel + ASA

Clopidogrel + ASA + oral anticoagulant | Good | * Study conducted solely outside the US
 |
| Lim, 2005143 | * ASA
* ASA + clopidogrel
 | Fair | * Groups were significantly different with respect to in hospital revascularization procedures.
* Statistical comparison of the results not reported.
* In hospital antithrombotic management and bleeding events not reported.
 |
| Lopes, 2010144 | * Warfarin
* Placebo
 | Good | * None
 |
| Maegdefessel, 2008145 | * Clopidogrel
 | Fair | * Study exclusion criteria were poorly described or not appropriate
* Study conducted solely outside the US
* Study was conducted only at a single site
 |
| Ng, 2008146 | * PPI
* Placebo
 | Good | * Study eligibility criteria were poorly described or not appropriate
* Study exclusion criteria were poorly described or not appropriate
* Study conducted solely outside the US
 |
| Ng, 2011147 | * Esomeprazole 20 mg
* Famotidine 40 mg
 | Good | * Study conducted solely outside the US
* Study was conducted only at a single site
 |
| Nguyen, 2007148GRACE | * ASA + thienopyridine
* ASA or thienopyridine
 | Good | * None
 |
| O’Donoghue, 2009149TRITON-TIMI 38 | * PPI
* No PPI
 | Good | * None
 |
| Ortolani, 2011150 | * PPI
* No PPI
 | Good | * None
 |
| Pekdemir, 2003151 | * 1 mo ASA 100 mg/day + clopidogrel 75 mg/day

Loading dose: 300 mg clopidogrel + 300 mg ASA + 10,000 IU heparin IV intraoperative Maintenance dose: 75 mg/day clopidogrel + 100 mg/day ASA* 6 mo ASA 100 mg/day + clopidogrel 75 mg/day

Loading dose: 300 mg clopidogrel + 300 mg ASA + 10,000 IU heparin IV intraoperativeMaintenance dose: 75 mg/day clopidogrel + 100 mg/day ASA | Fair | * Study conducted solely outside the US
* Study was conducted only at a single site
 |
| Persson, 2011152RIKS-HIA and SCAAR | * Warfarin
* Placebo
 | Good | * Study conducted solely outside the US
 |
| Quinn, 2004153Gusto IIb and PURSUIT | * ASA maintenance dose <150mg
* ASA maintenance dose ≥150mg
 | Good | * None
 |
| Rassen, 2009154 | * PPI
* Placebo
 | Good | * None
 |
| Ray, 2010155 | * PPI
* Placebo
 | Good | * None
 |
| Ren, 2011156 | * Omeprazole 20 mg
* Placebo
 | Poor | * Study did not report participants' comorbid conditions.
* Study conducted solely outside the US
 |
| Rossini, 2008157 | * Clopidogrel + ASA + Warfarin
* Clopidogrel + ASA
 | Good | * Study conducted solely outside the US
 |
| Rossini, 2011158 | * PPI
* No PPI
 | Good | * None
 |
| Roy, 2009159 | * Clopidogrel loading dose 300mg
* Clopidogrel loading dose 600mg
 | Poor | * Study was conducted only at a single site
 |
| Ruiz-Nodar, 2008160 | * Warfarin
* ASA
 | Good | * Study exclusion criteria were poorly described or not appropriate
* Study conducted solely outside the US
 |
| Ruiz-Nodar, 2012161 | * Warfarin
* No oral anticoagulant
 | Fair | * Study eligibility criteria were poorly described or not appropriate
* Study exclusion criteria were poorly described or not appropriate
* Study conducted solely outside the US
 |
| Sarafoff, 2010162 | * PPI
* Placebo
 | Good | * None
 |
| Schmidt, 2012163 | * Clopidogrel 75 mg maintenance dose
* PPI
 | Poor | * Study eligibility criteria were poorly described or not appropriate
* Study exclusion criteria were poorly described or not appropriate
* Study conducted solely outside the US
 |
| Schulz, 2009164 | * Clopidogrel + ASA

Loading dose: 600 mg clopidogrel + 500 mg ASAMaintenance dose: 75mg clopidogrel daily + ASA 100 mg twice daily | Fair | * Study conducted solely outside the US
 |
| Sibbald, 2010165 | * Early clopidogrel in-hospital
* No early clopidogrel in-hospital
 | Good | * None
 |
| Simon, 2011166FAST-MI | * PPI
* Placebo
 | Good | * None
 |
| So, 2009167 | * Clopidogrel
* Placebo
 | Fair | * Study conducted solely outside the US
* Study was conducted only at a single site
 |
| Steinhubl, 2002168CREDO | * Clopidogrel 1 mo
* Clopidogrel 12 mo
 | Good | * None
 |
| Stenestrand, 2005169RIKS-HIA | * ASA
* Oral anticoagulant
 | Good | * Study conducted solely outside the US
 |
| Stockl, 2010170 | * PPI
* Placebo
 | Good | * None
 |
| Tentzeris, 2010171 | * PPI
* No PPI
 | Good | * None
 |
| Tsai, 2011172 | * Clopidogrel + PPI
* Clopidogrel
 | Good | * None
 |
| Valgimigli, 2012173PRODIGY | * Clopidogrel

Loading dose: 300 or 600 mgMaintenance dose: 75 mgDuration 6 mo* Clopidogrel

Loading dose: 300 or 600 mgMaintenance dose: 75 mgDuration 24 mo | Good | * Study conducted solely outside the US
 |
| Valkhoff, 2011174 | * PPI
* Placebo
 | Poor | * Study eligibility criteria were poorly described or not appropriate
* Study exclusion criteria were poorly described or not appropriate
* Comparator(s) not well described
* Study conducted solely outside the US
* Study was conducted only at a single site
 |
| van Boxel, 2010175 | * Clopidogrel + PPI
* Clopidogrel
 | Fair | * Study eligibility criteria were poorly described or not appropriate
* Study exclusion criteria were poorly described or not appropriate
* Study conducted solely outside the US
 |
| Wu, 2010176 | * PPI
* Placebo
 | Good | * Study exclusion criteria were poorly described or not appropriate
* Study conducted solely outside the US
 |
| Yusuf, 2001177Peters, 2003178CURE | * Clopidogrel 300 mg loading dose, 75 mg daily
* Placebo
 | Good | * None
 |
| Zairis, 2010179 | * Omeprazole
* Placebo
 | Good | * Study conducted solely outside the US
* Study was conducted only at a single site
 |
| Zeymer, 2008180ACOS Registry | * ASA + clopidogrel
* ASA
 | Poor | * Study exclusion criteria were poorly described or not appropriate
* Diagnostic or therapeutic advances have been made in routine practice since the study was conducted
* Revascularization as well as postdischarge medications are poorly described
* Use of substandard alternative therapy (e.g., standard of treatment not from current practice)
 |

Abbreviations: ACT=activated clotting time; ASA=aspirin; BMS=bare metal stent;DES=drug-eluting stent; DM=diabetes mellitus; HTN=hypertension; IU=international units; IV=intravenous; mg=milligram/milligrams; MI=myocardial infarction; mo=month/months; PPI=proton pump inhibitor; sec=second/seconds